keep away from direct sunlight
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
1. Dauricine has pulmonary toxicity, can produce pulmonary injury in CD-1 mice by the metabolism of Dauricine mediated by CYP3A. 2. Dauricinec can pass the blood-brain barrier, and that P-glycoprotein has an important role in the transportation of Dauricine across the blood-brain barrier. 3. Dauricine may has anti-tumor effect, can inhibit tumor cells in urinary system and colon cancer cell proliferation, invasion; induce cell apoptosis by suppressing NF-kappaB activity and the expression profile of its downstream genes.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 7,000 | |||
5 mg | 在庫あり | ¥ 15,000 | |||
10 mg | 在庫あり | ¥ 26,000 | |||
25 mg | 在庫あり | ¥ 45,000 | |||
50 mg | 在庫あり | ¥ 67,500 | |||
100 mg | 在庫あり | ¥ 104,500 | |||
500 mg | 在庫あり | ¥ 226,500 |
説明 | 1. Dauricine has pulmonary toxicity, can produce pulmonary injury in CD-1 mice by the metabolism of Dauricine mediated by CYP3A. 2. Dauricinec can pass the blood-brain barrier, and that P-glycoprotein has an important role in the transportation of Dauricine across the blood-brain barrier. 3. Dauricine may has anti-tumor effect, can inhibit tumor cells in urinary system and colon cancer cell proliferation, invasion; induce cell apoptosis by suppressing NF-kappaB activity and the expression profile of its downstream genes. |
植物由来 |
分子量 | 624.77 |
分子式 | C38H44N2O6 |
CAS No. | 524-17-4 |
keep away from direct sunlight
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 91 mg/mL(145.7 mM)
Chloroform, Dichloromethane, Ethyl Acetate, Acetone, etc.: Soluble
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Dauricine 524-17-4 Apoptosis NF-Κb Others NF-κB Nuclear factor-κB Inhibitor inhibit Nuclear factor-kappaB inhibitor